"Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies."

During the past decade, Texas Oncology-Austin Midtown conducted 54 clinical trials. In the 10-year time frame, 54 clinical trials started and 31 clinical trials were completed, i.e. on average, 57.4% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 22 clinical trials were completed. i.e. 110% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Oncology-Austin Midtown" #1 sponsor was "Seagen Inc." with 9 trials, followed by "National Cancer Institute (NCI)" with 8 trials sponsored, "Sumitomo Pharma Oncology, Inc." with 5 trials sponsored, "Amgen" with 3 trials sponsored and "NRG Oncology" with 3 trials sponsored. Other sponsors include 45 different institutions and companies that sponsored additional 43 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Oncology-Austin Midtown" #1 collaborator was "National Cancer Institute (NCI)" with 12 trials as a collaborator, "NRG Oncology" with 7 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Cancer and Leukemia Group B" with 2 trials as a collaborator and "NCIC Clinical Trials Group" with 2 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Texas Oncology-Austin Midtown" are "Glioblastoma" (6 trials), "Advanced Solid Tumors" (4 trials), "Chronic Lymphocytic Leukemia" (4 trials), "Diffuse Large B-cell Lymphoma" (3 trials) and "Gliosarcoma" (3 trials). Many other conditions were trialed in "Texas Oncology-Austin Midtown" in a lesser frequency.

Most popular intervention types in "Texas Oncology-Austin Midtown" are "Drug" (67 trials), "Other" (16 trials), "Biological" (14 trials), "Radiation" (11 trials) and "Combination Product" (2 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (12 trials), "Bevacizumab" (8 trials), "Paclitaxel" (7 trials), "Quality-of-Life Assessment" (7 trials) and "Carboplatin" (6 trials). Other intervention names were less common.

The vast majority of trials in "Texas Oncology-Austin Midtown" are 65 trials for "All" genders, 11 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Oncology-Austin Midtown". undefined are not yet recruiting, 14 are recruiting, 24 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 29 completed trials in Texas Oncology-Austin Midtown, 1 suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Oncology-Austin Midtown, 21 "Phase 1" clinical trials were conducted, 34 "Phase 2" clinical trials and 31 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".